Ardent Health, Inc. ARDT R2KPHARMA
Company Overview
Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women's services, neurology, urology, and emergency services within inpatient and ambulatory care settings. It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free-standing emergency departments, and diagnostic imaging centers. The company operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. Ardent Health, Inc. was formerly known as Ardent Health Partners, Inc. and changed its name to Ardent Health, Inc. in June 2025. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health, Inc. is a subsidiary of EGI-AM Investments, L.L.C.
Why Investors Should Care
Trades at a P/E of 21.9, below the sector median of 25.4.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $6.32B (+6.0% YoY); net profit $135.81M.
- Trailing 12 Months Year-on-year growth — revenue -1.4%, earnings -77.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.2%, profit CAGR -10.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.23% |
| 1 Year: | -1.40% |
Compounded Profit Growth
| 5 Years: | -10.42% |
| 1 Year: | -77.10% |
Stock Price Performance
| 1 Year: | -3.16% |
| 6 Months: | +26.63% |
| 3 Months: | +12.05% |
| 1 Month: | +17.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.75 · Neutral
P/E of 21.91 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -10.4% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARDT Ardent Health, Inc. R2KPHARMA | 12.27 | 21.91 | $1.73B | 0.00% | 7.67% | 9.96% | 7.23% | -10.42% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.37B | 1.38B | 1.44B | 1.47B | - | - | 1.50B | 1.65B | 1.58B | 1.61B | 1.60B |
| Cost of Revenue | - | - | - | - | - | - | - | 916.51M | 942.34M | 952.84M | 928.92M | 929.98M |
| Gross Profit | - | - | - | - | - | - | - | 580.73M | 702.94M | 623.90M | 676.16M | 671.89M |
| Operating Expenses | - | - | - | - | - | - | - | 513.64M | 565.66M | 607.45M | 571.40M | 590.97M |
| Operating Income | - | - | - | - | - | - | - | 67.09M | 137.28M | 16.46M | 104.75M | 80.91M |
| EBITDA | - | - | - | - | - | - | - | 124.58M | 176.03M | 50.87M | 145.79M | 129.79M |
| Interest Expense | - | - | - | - | - | - | - | 14.18M | 14.73M | 13.91M | 12.38M | 12.21M |
| Pretax Income | - | - | - | - | - | - | - | 74.20M | 121.99M | -2.20M | 92.37M | 74.59M |
| Tax Provision | - | - | - | - | - | - | - | 15.23M | 26.29M | -3.41M | 18.11M | 16.10M |
| Net Income | 4.14M | 33.08M | 20.84M | 27.05M | 42.77M | - | - | 41.38M | 72.95M | -23.48M | 44.96M | 39.85M |
| Diluted EPS | - | 0.26 | 0.17 | 0.21 | 0.34 | 0.19 | - | 0.29 | 0.52 | -0.17 | - | 0.28 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 5.13B | 5.41B | 5.97B | 6.32B |
| Cost of Revenue | - | 3.37B | 3.38B | 3.57B | 3.74B |
| Gross Profit | - | 1.76B | 2.03B | 2.40B | 2.58B |
| Operating Expenses | - | 1.55B | 1.81B | 1.99B | 2.26B |
| Operating Income | - | 217.03M | 224.31M | 405.76M | 325.58M |
| EBITDA | - | 531.70M | 366.76M | 574.93M | 497.26M |
| Interest Expense | - | 82.05M | 74.31M | 65.58M | 55.20M |
| Pretax Income | - | 311.48M | 151.61M | 363.06M | 286.36M |
| Tax Provision | - | 46.11M | 22.64M | 63.35M | 56.22M |
| Net Income | - | 188.91M | 53.90M | 210.34M | 135.81M |
| Diluted EPS | - | 1.34 | 0.38 | 1.58 | 0.96 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 4.48B | 4.73B | 4.96B | 5.29B |
| Current Assets | - | 1.41B | 1.62B | 1.83B | 2.06B |
| Cash & Equivalents | - | 456.12M | 437.58M | 556.78M | 709.60M |
| Inventory | - | 107.15M | 105.48M | 115.09M | 118.59M |
| Receivables | - | 603.36M | 775.45M | 743.03M | 686.10M |
| Total Liabilities | - | 3.43B | 3.65B | 3.43B | 3.61B |
| Current Liabilities | - | 808.60M | 994.10M | 945.42M | 1.05B |
| Long Term Debt | - | 1.16B | 1.17B | 1.09B | 1.08B |
| Total Debt | - | 2.39B | 2.40B | 2.28B | 2.32B |
| Total Equity | 978.35M | 0 | 0 | 0 | 0 |
| Shares Outstanding | - | 140.96M | 140.96M | 142.75M | 142.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -38.36M | 221.70M | 315.03M | 470.51M |
| Investing Cash Flow | - | 46.58M | -137.98M | -220.46M | -214.23M |
| Financing Cash Flow | - | -270.33M | -102.26M | 24.64M | -103.47M |
| Capital Expenditure | - | -151.11M | -137.41M | -187.51M | -211.90M |
| Free Cash Flow | - | -189.47M | 84.29M | 127.52M | 258.61M |
| Net Change in Cash | - | -262.11M | -18.55M | 119.21M | 152.82M |
| Dividends Paid | - | 174.81M | 0 | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 34.4% | 37.6% | 40.2% | 40.9% |
| Operating Margin % | - | 4.2% | 4.1% | 6.8% | 5.1% |
| Net Margin % | - | 3.7% | 1.0% | 3.5% | 2.1% |
| ROE % | - | - | - | - | - |
| ROCE % | - | 5.9% | 6.0% | 10.1% | 7.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Chai Trust Co LLC | 54.77% | 77.25M | $872.89M |
| 2 | Ventas Inc | 6.62% | 9.34M | $105.57M |
| 3 | Blackrock Inc. | 1.54% | 2.18M | $24.59M |
| 4 | Ameriprise Financial, Inc. | 1.50% | 2.11M | $23.85M |
| 5 | Goldentree Asset Management LP | 1.12% | 1.58M | $17.86M |
| 6 | AQR Capital Management, LLC | 1.03% | 1.45M | $16.36M |
| 7 | Castleknight Management LP | 0.76% | 1.08M | $12.17M |
| 8 | Vanguard Capital Management LLC | 0.68% | 963.83K | $10.89M |
| 9 | Bridgeway Capital Management, LLC | 0.60% | 841.13K | $9.50M |
| 10 | Geode Capital Management, LLC | 0.44% | 620.95K | $7.02M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARDT
Ardent Health, Inc. (ARDT) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE9sR2Z0TDhUTVVCNFRPeXNzQUEzaWRYNkFiZDAwYWpnUnYtUFZSWXJIVFhQM3VpdGlLVWdEZVZONVZ5R2hmZF9vVmRpTEhEMFRBT0E?oc=5" target="_blank">Ardent Health, Inc. (ARDT) Stock Price, News, Quote & Hi…
Ardent Health, Inc. Estimates – NYSE:ARDT - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE9aM1JMdDBXY3ZLX19XTmdrdEtnaElPZVg3SVdhVnRCMjUtNWg2azlyam91R1RydUh1U0w5RkRrU0ZvaWZ2aVEteUlQVUEyRzNObHB2OEJkbTNOWkNWazFNeHV0cHg5NGVHZER3Wld4OFJpTjJqM2c?oc=5" target="_blank">Ardent H…
Ardent Health(ARDT) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMi_AJBVV95cUxPWG1yVjl5YUtqSmwwalFCaWoyb1VzbTJOczNla1dmekwzMWxYbXdGbFNTVjFqLXdQNWlIR0xLbGVxZFg4Qy1SWGVyUV9tUmQ0OFRtUXk3ekdDRWRHQ0RqbHVRV1h1bmZCV0p4cUs1OUNldjJobkxKV3VIRUlJdVdOWUVSZEIwNzU3ZTZfNn…
Ardent Health (ARDT) Stock Looks Like A Bargain As It Gains 43% YTD - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQbkdHbHA4ZGRkdF9OLUlqUjZIRE5KNlNndld6ZkVDWDdWd0Q5LUVsXzRrY2lGdEJNeko2bkJKaEQ5Q1ZYTUpWWW51NWIyVXU2bk5JTnE4RngxSGdQaE55Wi1zalRyeVNEVW1OTzJJdHV6YnhiOHBVaFhnRXJXUkxRdUgyN1lKYzh0bVdENl…
Should Digital Leadership Change Require Action From Ardent Health (ARDT) Investors? - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPZVJHT29oNzU5RUV4azNrY2dmV0wtbHBlVlJMX3F2NUpyTWxKeHM0OXlTSVFIR1ZkWnY5WVZkZVdDMlU0STd2RW1iM0JlSmw4YzJLazNRYU9fMk9KU2JWaTdJNjd4WWZ2Vk9WRXBOaURwdmlmR3NVVVA4Tkoyc3pRZ3FYWDZxbExKdGxidV…
Ardent Health reclassifies former CEO’s exit as termination for cause By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNektPUmoxTXhsS3hfOG5wYWZHcXpYTTUzQk1BZU5aRVdETHJHNFJBVE9UNnFtcEM3a1pha3pFVFU3d2tiR01fSEtpc1NDc3lBSUFja0RfbzQtYnJUZkV0bWQtekNGakI2dGpUXzVQUXhtMUFfdThPNEIxSHNNaFhWcnptLWhnUG5fX3BYcm…
ARDT — Frequently Asked Questions
What is the current share price of Ardent Health, Inc. (ARDT)?
As of 2026-10-23 16:27 PDT, Ardent Health, Inc. (ARDT) trades at $12.27 on NYSE. Its 52-week range is $7.83 to $15.21.
What is the market capitalisation of ARDT?
Ardent Health, Inc. (ARDT) has a market capitalisation of $1.73B on NYSE.
What is the P/E ratio of ARDT?
ARDT trades at a trailing price-to-earnings (P/E) ratio of 21.91. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.19.
What is the return on equity (ROE) of ARDT?
ARDT has a return on equity (ROE) of 9.96%. Its return on capital employed (ROCE) is 7.67%.
Is ARDT a good stock to buy?
This page provides a data-driven analysis of Ardent Health, Inc. (ARDT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.